Invesco Ltd. · IVZ · FY2026 Q2 · Calendar Q3 2026
Invesco: Record inflows support higher margins and product expansion
The supplied Q2 analysis supports a constructive operating thesis for Invesco: record inflows, ETF demand, product launches, partnerships, and operating leverage are reinforcing growth. That thesis remains conditional on sustaining flows and margins while managing fee compression and hybrid-platform execution.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about IVZ FY2026 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the supplied Q2 analysis describes stronger inflows, a higher operating margin, continued QQQ international expansion, more than 50 new products launched during the year, and new tokenized-Treasury and Canadian sub-advisory developments. The focus also shifted toward sustaining high-30s margins while completing the hybrid-platform rollout.
Guidance delta
Management guidance sentiment was maintained; the supplied analysis highlights a sustained high-30s operating-margin target and continued platform and product expansion.
Key takeaways
- Record net long-term inflows and higher assets under management indicate broad demand across regions and products.
- ETF demand, particularly in the QQQ franchise, remained the central growth engine in the supplied analysis.
- Operating-margin expansion and balance-sheet deleveraging strengthen the operating backdrop.
- New products and partnerships broaden exposure to active ETFs, tokenized Treasuries, private markets, and international distribution.
- The main offsets are fee compression, flow volatility, platform implementation costs, and private-market risk.
Management priorities
- Expand the QQQ franchise internationally and through product extensions.
- Launch additional active ETFs and continue the BulletShares rollout.
- Complete the hybrid investment platform implementation and pursue related cost efficiencies.
- Deepen partnerships and sub-advisory relationships across private markets and international channels.
- Maintain capital returns through buybacks and dividends.
Follow IVZ with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 24, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | In Line | In Line | Maintain | Sep 9, 2026 |
| TD Cowen | Buy | Buy | Maintain | Aug 13, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 29, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 29, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 29, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 17, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Apr 29, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Apr 10, 2026 |
| Argus Research | Buy | Buy | Maintain | Jan 28, 2026 |
| Deutsche Bank | Buy | Hold | Upgrade | Dec 17, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Oct 2, 2025 |
| Citigroup | Neutral | Neutral | Maintain | Sep 29, 2025 |
| Wells Fargo | Equal Weight | Underweight | Upgrade | Jul 11, 2025 |
| UBS | Neutral | Neutral | Maintain | Feb 3, 2025 |
| Keefe, Bruyette & Woods | Market Perform | Market Perform | Maintain | Jan 29, 2025 |
| Credit Suisse | Neutral | Underperform | Upgrade | Mar 29, 2023 |
| Jefferies | Hold | Buy | Downgrade | Jun 7, 2019 |
| Keefe Bruyette & Woods | Market Perform | Outperform | Downgrade | Jul 13, 2018 |
| Argus | Buy | Buy | Maintain | May 5, 2018 |
| Bank of America | Neutral | Buy | Downgrade | Jan 8, 2018 |
| Keefe, Bruyette& Woods | Perform | Outperform | Downgrade | Dec 12, 2016 |
| Susquehanna | Positive | Positive | Maintain | Sep 3, 2015 |
| PiperJaffray | Overweight | Overweight | Maintain | Jun 3, 2015 |
| Sterne Agee | Buy | Neutral | Upgrade | Jan 7, 2015 |
| Evercore Partners | Equal Weight | Equal Weight | Maintain | Jul 10, 2013 |
| Nomura | Buy | Buy | Maintain | May 1, 2013 |
| Stifel Nicolaus | Buy | Buy | Maintain | Feb 1, 2013 |
| Stifel | Buy | Buy | Maintain | Feb 1, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $30.74. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| RBC Capital | Analyst unavailable | $39 | $32.02 | +26.9% | Aug 13, 2026 |
| Evercore ISI | Analyst unavailable | $35 | $32.05 | +13.9% | Aug 10, 2026 |
| Barclays | Analyst unavailable | $32 | $29.43 | +4.1% | Jul 29, 2026 |
| Barclays | Analyst unavailable | $31 | $28.4 | +0.8% | Jul 14, 2026 |
| Evercore ISI | Analyst unavailable | $32 | $29.08 | +4.1% | Jul 10, 2026 |
| Evercore ISI | Analyst unavailable | $31 | $27.79 | +0.8% | Jun 8, 2026 |
| Goldman Sachs | Alexander Blostein | $30 | $25.88 | -2.4% | Apr 29, 2026 |
| Barclays | Analyst unavailable | $26 | $25.88 | -15.4% | Apr 29, 2026 |
| RBC Capital | Kenneth Lee | $31 | $24.95 | +0.8% | Apr 21, 2026 |
| Evercore ISI | Analyst unavailable | $27 | $23.63 | -12.2% | Apr 10, 2026 |
| BMO Capital | Analyst unavailable | $28 | $23.63 | -8.9% | Apr 10, 2026 |
| RBC Capital | Kenneth Lee | $33 | $27.76 | +7.4% | Jan 28, 2026 |
| Cowen & Co. | Analyst unavailable | $34.5 | $27.28 | +12.2% | Jan 28, 2026 |
| Argus Research | Stephen Biggar | $31 | $27.26 | +0.8% | Jan 28, 2026 |
| Goldman Sachs | Analyst unavailable | $29.5 | $27.16 | -4.0% | Jan 28, 2026 |
| Barclays | Analyst unavailable | $29 | $27.16 | -5.7% | Jan 28, 2026 |
| Morgan Stanley | Analyst unavailable | $29 | $28.4 | -5.7% | Jan 26, 2026 |
| RBC Capital | Kenneth Lee | $35 | $28.95 | +13.9% | Jan 21, 2026 |
| Goldman Sachs | Alexander Blostein | $28.75 | $28.25 | -6.5% | Jan 15, 2026 |
| Barclays | Benjamin Budish | $30 | $28.25 | -2.4% | Jan 15, 2026 |
| Goldman Sachs | Alexander Blostein | $28.25 | $28.16 | -8.1% | Jan 6, 2026 |
| Morgan Stanley | Analyst unavailable | $28 | $26.82 | -8.9% | Dec 17, 2025 |
| Deutsche Bank | Analyst unavailable | $31 | $26.03 | +0.8% | Dec 17, 2025 |
| Barclays | Benjamin Budish | $28 | $26.99 | -8.9% | Dec 12, 2025 |
| BMO Capital | Analyst unavailable | $30 | $26.54 | -2.4% | Dec 10, 2025 |
| Goldman Sachs | Analyst unavailable | $25.5 | $23.81 | -17.0% | Nov 25, 2025 |
| Fundamental Research | Analyst unavailable | $27 | $23.66 | -12.2% | Oct 31, 2025 |
| RBC Capital | Kenneth Lee | $25 | $24.02 | -18.7% | Oct 30, 2025 |
| Goldman Sachs | Analyst unavailable | $26.5 | $24.35 | -13.8% | Oct 29, 2025 |
| Barclays | Analyst unavailable | $24 | $22.84 | -21.9% | Oct 21, 2025 |
| Morgan Stanley | Analyst unavailable | $26 | $23.98 | -15.4% | Oct 6, 2025 |
| Evercore ISI | Glenn Schorr | $24 | $21.99 | -21.9% | Sep 5, 2025 |
| Wells Fargo | Michael Brown | $18 | $17.43 | -41.4% | Jul 11, 2025 |
| Barclays | Benjamin Budish | $19 | $18.04 | -38.2% | Oct 23, 2024 |
| Wells Fargo | Michael Brown | $16 | $15.8 | -48.0% | Sep 11, 2024 |
| RBC Capital | Kenneth Lee | $16 | $14.52 | -48.0% | Apr 25, 2024 |
| Deutsche Bank | Brian Bedell | $17 | $16.53 | -44.7% | Apr 5, 2024 |
| Morgan Stanley | Analyst unavailable | $23 | $18.96 | -25.2% | Apr 27, 2022 |
| Deutsche Bank | Brian Bedell | $24 | $19.03 | -21.9% | Apr 27, 2022 |
| Morgan Stanley | Analyst unavailable | $25 | $20.39 | -18.7% | Apr 25, 2022 |
| RBC Capital | Kenneth Lee | $23 | $21.41 | -25.2% | Jan 24, 2022 |
| Barclays | Jeremy Campbell | $25 | $26.29 | -18.7% | Apr 30, 2021 |
| Argus Research | Stephen Biggar | $33 | $26.51 | +7.4% | Apr 28, 2021 |
| Wells Fargo | Christopher Harris | $25 | $25.23 | -18.7% | Apr 13, 2021 |
Track every rating change on IVZ the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationInvesco Ltd. engages in the investment management business. Its products include mutual funds, unit trusts, exchange-traded funds, closed-end funds, and retirement plans. The company was founded in December 1935 and is headquartered in Atlanta, GA.
Historical context
All IVZ earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PUK Prudential plc | FY2026 Q2 · Calendar Q3 2026 | -40.9% | -0.5% | Prudential sustains growth and capital returns focus in H1 2026 |
| CM Canadian Imperial Bank of Commerce | FY2026 Q3 · Calendar Q3 2026 | +8.9% | -2.8% | CIBC Q3: Broad growth, resilient credit and expanded AI rollout |
| TD The Toronto-Dominion Bank | FY2026 Q3 · Calendar Q3 2026 | +13.8% | +1.4% | TD emphasizes growth investments alongside disciplined capital management |
| RY Royal Bank of Canada | FY2026 Q3 · Calendar Q3 2026 | +6.2% | -1.3% | RBC reports record Q3 earnings while investing for growth |
| AFRM Affirm Holdings, Inc. | FY2026 Q4 · Calendar Q3 2026 | +1230.3% | +0.3% | Affirm's most profitable quarter shifts focus to product execution |
Latest beats and misses
Who reports nextBeat on EPS
- AZOFY2026 Q4 · September 22, 2026+3.6% EPS+3.3% move
- FPSFY2026 Q4 · September 15, 2026+4.3% EPS+9.5% move
- TCOMFY2026 Q2 · September 15, 2026+22.3% EPS+3.0% move
- KRFY2026 Q2 · September 11, 2026+2.8% EPS+2.7% move
- ADBEFY2026 Q3 · September 10, 2026+0.8% EPS+1.4% move
- ORCLFY2027 Q1 · September 10, 2026+10.3% EPS-1.7% move
Get the IVZ recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-28T15:03:54.450010+00:00
- FN2 earnings calendar · 2026-09-02T01:23:14.593608+00:00
- Polygon adjusted daily market bars · 2026-09-24T03:20:56.090675+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-24T03:20:56.087459+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-24. For educational purposes only; not investment advice.